Skip to main content
Sign In
 

Lynn E. Heasley

Professor and Chair


Lynn Heasley
Dr. Lynn E. Heasley

Department of Craniofacial Biology
School of Dental Medicine
Mail Stop 8120
12801 E. 17th Avenue
Aurora, CO  80045

Phone: 303-724-4578
Fax: 303-724-4580
Email: lynn.heasley@ucdenver.edu

Education:

  • Postdoctoral Fellow, Division of Basic Sciences, National Jewish Center for Immunology and Respiratory Medicine, Denver, CO
  • Postdoctoral Fellow, Department of Biochemistry, University of Massachusetts Medical Center, Worcester, MA
  • PhD, Pharmacology, University of California at San Diego, La Jolla, CA
  • BA, Chemistry/Biology, Point Loma College, San Diego, CA

Honors and Awards:

  • VA Merit Researcher, Eastern Colorado VA
  • Full Member, NIH Tumor Cell Biology Study Section
  • Editorial Board, the Journal of Biological Chemistry

Departmental Affiliations:

  • Department of Craniofacial Biology, School of Dental Medicine
  • Department of Pharmacology, School of Medicine

Research Interests

  • Lung Cancer
  • Head and Neck Squamous Cell Carcinoma
  • Receptor Tyrosine Kinase Signaling Networks
  • Functional Genomics and Synthetic Lethal Screens
  • Experimental Therapeutics with Pipeline and Investigational Cancer Drugs

Recent Publications:

  • Gurule NJ and Heasley LE. (2018) Linking tyrosine kinase inhibitor-mediated inflammation with normal epithelial cell homeostasis and tumor therapeutic responses. Cancer Drug Res. In press.
  • Merrick DT, Edwards MG, Franklin WA, Sugita M, Keith RL, Miller YE, Friedman MB, Dwyer-Nield LD, Tennis MA, O'Keefe MC, Donald EJ, Malloy JM, van Bokhoven A, Wilson S, Koch PJ, O'Shea C, Coldren C, Orlicky DJ, Lu X, Baron AE, Hickey G, Kennedy TC, Powell R, Heasley L, Bunn PA, Geraci M, Nemenoff RA. (2018)
    Altered cell-cycle control, inflammation and adhesion in high-risk persistent bronchial dysplasia. Cancer Res. In press. PMID: 29997230
  • Bhatia S, Sharma J, Bukkapatnam S, Oweida A, Lennon S, Phan A, Milner D, Uyanga N, Jimeno A, Raben D, Somerset H, Heasley L, Karam SD. (2018) Inhibition of EphB4-Ephrin-B2 Signaling Enhances Response to Cetuximab-Radiation Therapy in Head and Neck Cancers. Clin Cancer Res. In press. PMID: 29848571
  • Kleczko EK, Heasley LE. (2018) Mechanisms of rapid cancer cell reprogramming initiated by targeted receptor tyrosine kinase inhibitors and inherent therapeutic vulnerabilities. Mol Cancer. 17(1):60. PMID: 29458371 PMCID: PMC5817864
  • Pilling AB, Kim J, Estrada-Bernal A, Zhou Q, Le AT, Singleton KR, Heasley LE, Tan AC, DeGregori J, Doebele RC. (2018) ALK is a critical regulator of the MYC-signaling axis in ALK positive lung cancer. Oncotarget. 9(10):8823-8835. PMID: 29507657 PMCID: PMC5823650
  • Li HY, McSharry M, Bullock B, Nguyen TT, Kwak J, Poczobutt JM, Sippel TR, Heasley LE, Weiser-Evans MC, Clambey ET, Nemenoff RA. (2017) The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade. Cancer Immunol Res. 5(9):767-777. PMID: 28819064 PMCID: PMC5787226
  • Oweida A, Lennon S, Calame D, Korpela S, Bhatia S, Sharma J, Graham C, Binder D, Serkova N, Raben D, Heasley L, Clambey E, Nemenoff R, Karam SD. (2017) Ionizing radiation sensitizes tumors to PD-L1 immune checkpoint blockade in orthotopic murine head and neck squamous cell carcinoma. Oncoimmunology. 6(10):e1356153. PMID: 29123967 PMCID: PMC5665079
  • Ohm AM, Tan AC, Heasley LE, Reyland ME. (2017) Co-dependency of PKCδ and K-Ras: inverse association with cytotoxic drug sensitivity in KRAS mutant lung cancer. Oncogene. 36(30):4370-4378. PMID: 28368426 PMCID: PMC5532068
  • Vaishnavi A, Schubert L, Rix U, Marek LA, Le AT, Keysar SB, Glogowska MJ, Smith MA, Kako S, Sumi NJ, Davies KD, Ware KE, Varella-Garcia M, Haura EB, Jimeno A, Heasley LE, Aisner DL, Doebele RC. (2017)  EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases. Cancer Res. 77(13):3551-3563. PMID: 28428274 PMCID: PMC5516930
  • Singleton KR, Earley KT, Heasley LE. (2017) Analysis of Drug Resistance Using Kinome-Wide Functional Screens. Methods in Molec Biol (Clifton, N.J.). 1636:163-177. PMID: 28730479
  • Ryall KA, Shin J, Yoo M, Hinz TK, Kim J, Kang J, Heasley LE, Tan AC. (2015) Identifying kinase dependency in cancer cells by integrating high-throughput drug screening and kinase inhibition data. Bioinformatics. 2015; 31(23):3799-806.PMID: 26206305 PMCID: PMC4675831
  • Singleton KR, Hinz TK, Kleczko EK, Marek LA, Kwak J, Harp T, Kim J, Tan AC, Heasley LE. (2015) Kinome RNAi Screens Reveal Synergistic Targeting of MTOR and FGFR1 Pathways for Treatment of Lung Cancer and HNSCC. Cancer Res. 2015; 75(20):4398-406. NIHMSID: NIHMS718410
  • Göke F, Franzen A, Hinz TK, Marek LA, Yoon P, Sharma R, Bode M, von Maessenhausen A, Lankat-Buttgereit B, Göke A, Golletz C, Kirsten R, Boehm D, Vogel W, Kleczko EK, Eagles JR, Hirsch FR, Van Bremen T, Bootz F, Schroeck A, Kim J, Tan AC, Jimeno A, Heasley LE, Perner S. (2015) FGFR1 Expression Levels Predict BGJ398 Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell Cancers. Clin Can Res 21(19):4356-64. PMID: 26015511 PMCID: PMC4592392


© The Regents of the University of Colorado, a body corporate. All rights reserved.

Accredited by the Higher Learning Commission. All trademarks are registered property of the University. Used by permission only.